Published in J Virol on June 10, 2009
NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7. Cell Host Microbe (2016) 1.46
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
TLR/NCR/KIR: Which One to Use and When? Front Immunol (2014) 1.03
Killing of avian and Swine influenza virus by natural killer cells. J Virol (2010) 1.03
The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. J Biol Chem (2012) 0.98
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther (2009) 0.98
Characterization of a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK cell repertoire. Blood (2013) 0.97
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics (2015) 0.94
NKp46 defines ovine cells that have characteristics corresponding to NK cells. Vet Res (2011) 0.93
Mechanisms of Oncolysis by Paramyxovirus Sendai. Acta Naturae (2015) 0.92
Safety and clinical usage of newcastle disease virus in cancer therapy. J Biomed Biotechnol (2011) 0.87
The structural basis of ligand recognition by natural killer cell receptors. J Biomed Biotechnol (2011) 0.87
Influenza virus uses its neuraminidase protein to evade the recognition of two activating NK cell receptors. J Infect Dis (2014) 0.87
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel) (2013) 0.86
Structural insights into activation of antiviral NK cell responses. Immunol Rev (2012) 0.85
2B4 utilizes ITAM-containing receptor complexes to initiate intracellular signaling and cytolysis. Mol Immunol (2011) 0.84
Evasion of natural killer cells by influenza virus. J Leukoc Biol (2010) 0.83
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proc Natl Acad Sci U S A (2016) 0.82
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol (2014) 0.82
Multiparametric analysis of host response to murine cytomegalovirus in MHC class I-disparate mice reveals primacy of Dk-licensed Ly49G2+ NK cells in viral control. J Immunol (2013) 0.82
Sialoside-based pattern recognitions discriminating infections from tissue injuries. Curr Opin Immunol (2011) 0.82
Endocytosis and intracellular trafficking of human natural killer cell receptors. Traffic (2009) 0.81
Identification of putative novel O-glycosylations in the NK killer receptor Ncr1 essential for its activity. Cell Discov (2015) 0.80
NK cells and their ability to modulate T cells during virus infections. Crit Rev Immunol (2014) 0.80
Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines. Front Oncol (2014) 0.80
Human herpesviridae methods of natural killer cell evasion. Adv Virol (2012) 0.80
Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression. Front Immunol (2017) 0.78
Expression and function of NKp46 W32R: the human homologous protein of mouse NKp46 W32R (Noé). Sci Rep (2017) 0.77
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines (2016) 0.77
NKp46 Clusters at the Immune Synapse and Regulates NK Cell Polarization. Front Immunol (2015) 0.77
Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands. J Biol Chem (2013) 0.77
The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity. Oncotarget (2016) 0.76
Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent. J Cancer (2016) 0.75
Immunomodulatory effects of Newcastle disease virus AF2240 strain on human peripheral blood mononuclear cells. Int J Med Sci (2014) 0.75
Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virother (2015) 0.75
Emerging role of Natural killer cells in oncolytic virotherapy. Immunotargets Ther (2015) 0.75
Recognition and Regulation of T Cells by NK Cells. Front Immunol (2016) 0.75
NKp46 recognizes the sigma1 protein of reovirus: Implications for reovirus-based cancer therapy. J Virol (2017) 0.75
Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. Sci Rep (2017) 0.75
Zika virus escapes NK cell detection by upregulating MHC class I molecules. J Virol (2017) 0.75
NK cell recognition. Annu Rev Immunol (2005) 14.40
Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 7.07
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol (1979) 5.06
Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity (2001) 5.04
Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol (2006) 5.00
Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature (2001) 4.76
Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol (2000) 4.10
Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med (1997) 3.57
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med (2001) 2.64
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol (2005) 2.55
Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol (2001) 2.25
Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol (1999) 2.23
Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med (2003) 2.20
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20
Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion. J Virol (2004) 2.09
Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nat Rev Immunol (2007) 1.84
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol (2004) 1.84
Killer immunoglobulin-like receptors. Curr Opin Immunol (2004) 1.83
Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol (2001) 1.72
NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci U S A (2005) 1.67
Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol (2006) 1.48
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Activation and self-tolerance of natural killer cells. Immunol Rev (2006) 1.46
Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol (2004) 1.43
Newcastle disease virus selectively kills human tumor cells. J Surg Res (1992) 1.40
The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol (2006) 1.37
The avian response to Newcastle disease virus. Dev Comp Immunol (2000) 1.35
Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J Immunol (2006) 1.34
NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens (2003) 1.30
Newcastle disease virus contains a linkage-specific glycoprotein sialidase. Application to the localization of sialic acid residues in N-linked oligosaccharides of alpha 1-acid glycoprotein. J Biol Chem (1982) 1.29
Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One (2007) 1.26
Direct binding of human NK cell natural cytotoxicity receptor NKp44 to the surfaces of mycobacteria and other bacteria. Infect Immun (2008) 1.23
MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol (2004) 1.23
Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol (2003) 1.21
The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol (2002) 1.17
Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J Infect Dis (2007) 1.16
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther (1999) 1.13
Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry (2007) 1.12
Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol (2006) 1.12
Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology (2007) 1.12
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther (1999) 1.10
Immunization with virus-modified tumor cells. Semin Oncol (1998) 1.10
Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. Eur J Immunol (2003) 1.08
TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol (2003) 1.08
Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother (2004) 1.05
The role of natural killer cells in tumor control--effectors and regulators of adaptive immunity. Springer Semin Immunopathol (2005) 1.04
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother (2008) 1.03
A Duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum-parasitized erythrocytes by natural killer cells. J Infect Dis (2007) 1.02
Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother (1994) 0.99
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother (1992) 0.98
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol (2001) 0.97
Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res (1999) 0.91
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol (2007) 0.89
Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int J Cancer (2007) 0.89
A transporter associated with antigen-processing independent vacuolar pathway for the MHC class I-mediated presentation of endogenous transmembrane proteins. J Immunol (2007) 0.88
Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol (2000) 0.87
Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther (2000) 0.86
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol (1997) 0.86
High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int J Oncol (2004) 0.85
Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. Int Immunol (1996) 0.85
Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses. Cancer Biother Radiopharm (1997) 0.84
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. Melanoma Res (2006) 0.84
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res (1997) 0.82
The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci U S A (2005) 2.47
Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol (2003) 2.15
Impaired assembly of the major histocompatibility complex class I peptide-loading complex in mice deficient in the oxidoreductase ERp57. Nat Immunol (2005) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol (2004) 1.84
Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J (2004) 1.73
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol (2013) 1.70
Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood (2005) 1.61
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS One (2007) 1.61
Integration of activating and inhibitory receptor signaling by regulated phosphorylation of Vav1 in immune cells. Sci Signal (2011) 1.57
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (2012) 1.56
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood (2008) 1.56
SPODOBASE: an EST database for the lepidopteran crop pest Spodoptera. BMC Bioinformatics (2006) 1.48
Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2008) 1.47
Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A (2002) 1.45
Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res (2011) 1.41
Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res (2008) 1.40
Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 1.37
High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res (2005) 1.35
The TREM-1/DAP12 pathway. Immunol Lett (2007) 1.33
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31
Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur J Immunol (2005) 1.27
Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One (2007) 1.26
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
The internal sequence of the peptide-substrate determines its N-terminus trimming by ERAP1. PLoS One (2008) 1.23
The auditory sensitivity is increased in tinnitus ears. J Neurosci (2013) 1.22
Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res (2011) 1.21
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood (2004) 1.19
A major role for tapasin as a stabilizer of the TAP peptide transporter and consequences for MHC class I expression. Eur J Immunol (2003) 1.19
Recruitment of MHC class I molecules by tapasin into the transporter associated with antigen processing-associated complex is essential for optimal peptide loading. J Immunol (2002) 1.18
Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med (2005) 1.18
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest (2014) 1.17
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol (2009) 1.17
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer (2013) 1.17
Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest (2004) 1.16
A conserved, lipid-mediated sorting mechanism of yeast Ist2 and mammalian STIM proteins to the peripheral ER. Traffic (2009) 1.16
Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst (2007) 1.15
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother (2012) 1.15
Immune synapse formation determines interaction forces between T cells and antigen-presenting cells measured by atomic force microscopy. Proc Natl Acad Sci U S A (2009) 1.14
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer (2008) 1.12
Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology (2007) 1.12
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer (2009) 1.11
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol (2009) 1.08
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol (2003) 1.08
T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med (2003) 1.08
Natural killer cells and solid tumors. J Innate Immun (2011) 1.07
Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res (2009) 1.07
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood (2013) 1.06
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res (2002) 1.06
Inhibitory receptor signals suppress ligation-induced recruitment of NKG2D to GM1-rich membrane domains at the human NK cell immune synapse. J Immunol (2007) 1.05
Non-T cell activation linker (NTAL) negatively regulates TREM-1/DAP12-induced inflammatory cytokine production in myeloid cells. J Immunol (2007) 1.05
Gene transfer and genetic modification of embryonic stem cells by Cre- and Cre-PR-expressing MESV-based retroviral vectors. J Gene Med (2004) 1.04
Regulation of nitrogen fixation in the phototrophic purple bacterium Rhodobacter capsulatus. J Mol Microbiol Biotechnol (2002) 1.04
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics (2010) 1.03
The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res (2006) 1.02
Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res (2003) 1.02
Regulation of 2B4 (CD244)-mediated NK cell activation by ligand-induced receptor modulation. Eur J Immunol (2006) 1.01
Fine-tuning of immune responses by SLAM-related receptors. J Leukoc Biol (2005) 1.01
2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol (2006) 1.00
Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer (2003) 1.00
Memory of infections: an emerging role for natural killer cells. PLoS Pathog (2013) 1.00
Cutting edge: NTB-A activates NK cells via homophilic interaction. J Immunol (2004) 0.99
The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. J Biol Chem (2012) 0.98
Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance. Eur J Immunol (2006) 0.98
Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res (2004) 0.97
Densovirus infectious pathway requires clathrin-mediated endocytosis followed by trafficking to the nucleus. J Virol (2009) 0.97
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology (2009) 0.97
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol (2008) 0.96
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines (2009) 0.96
Regulation of NK cell activity by 2B4, NTB-A and CRACC. Front Biosci (2008) 0.96
Natural killer cells: fighting viruses and much more. Nat Immunol (2011) 0.96
Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood (2013) 0.96
Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon. J Immunol (2006) 0.95
Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology (2005) 0.95
Virally infected mouse liver endothelial cells trigger CD8+ T-cell immunity. Gastroenterology (2009) 0.95
Dynamic differentiation of activated human peripheral blood CD8+ and CD4+ effector memory T cells. J Immunol (2005) 0.95